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Abstract 
Background: Data regarding long-term association of metabolic syndrome (MetS) with adverse outcomes are 
conflicting. We aim to determine the independent association of MetS (based on its different definitions) with 20 year 
all-cause mortality among patients with stable coronary artery disease (CAD).
Methods: Our study comprised 15,524 patients who were enrolled in the Bezafibrate Infarction Prevention registry 
between February 1, 1990, and October 31, 1992, and subsequently followed-up for the long-term mortality through 
December 31, 2014. MetS was defined according to two definitions: The International Diabetes Federation (IDF); and 
the National Cholesterol Education Program–Third Adult Treatment Panel (NCEP).
Results: According to the IDF criteria 2122 (14%) patients had MetS, whereas according to the NCEP definition 7446 
(48%) patients had MetS. Kaplan–Meier survival analysis showed that all-cause mortality was significantly higher 
among patients with MetS defined by both the IDF (67 vs. 61%; log rank-p < 0.001) as well as NCEP (67 vs. 54%; log 
rank-p < 0.001) criteria. Multivariate adjusted mortality risk was 17% greater [Hazard Ratio (HR) 1.17; 95% Confidence 
Interval (CI) 1.07–1.28] in patients with MetS according to IDF and 21% (HR 1.21; 95% CI 1.13–1.29) using the NCEP 
definition. Subgroup analysis demonstrated that long-term increased mortality risk associated with MetS was consist-
ent among most clinical subgroups excepted patients with renal failure (p value for interaction < 0.05).
Conclusions: Metabolic syndrome is independently associated with an increased 20-year all-cause mortality risk 
among patients with stable CAD. This association was consistent when either the IDF or NCEP definitions were used.
Trial registration retrospective registered
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Background
The metabolic syndrome (MetS) is a constellation of car-
diovascular risk factors centered around obesity, abnor-
mal glucose metabolism, hypertension and atherogenic 
dyslipidemia [1, 2].
These risk factors tend to cluster together in patients, 
and when they do, they substantially increase the risk for 
the development of cardiovascular disease [2]. The preva-
lence of the MetS is increasing, coincident with increas-
ing levels of obesity related to sedentary lifestyles and 
poor nutrition habits [3–6].
The association of the MetS with increased risk of 
adverse cardiovascular outcomes, morbidity and mor-
tality is well established [7–13]. However, controversy 
remains regarding independent character of this associa-
tion as well as regarding the additional value of the MetS 
in the risk estimation on top of its individual compo-
nents. Furthermore, recent studies showed that MetS is 
associated with an increased risk of cardiovascular mor-
tality and re-infarction in patients with cardiovascular 
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disease [14, 15], however, these studies are mostly lim-
ited to patients after a recent acute coronary syndrome 
(ACS) or after revascularization, and there is limited data 
regarding patients with stable coronary disease without 
revascularization procedures [16]. Furthermore, to date 
the follow-up period in the majority of studies exploring 
the association of MetS and mortality is less than 3 years 
[16–21] and these studies have predominantly explored 
cardiovascular mortality and not all-cause mortality as 
their primary outcome [16–21].
Thus, limited data exist regarding the association 
between the presence of MetS and long-term all-cause 
mortality among patients with stable coronary artery dis-
ease (CAD), especially among those who have not under-
gone prior coronary revascularization or recent ACS. It is 
unclear whether this association is independent following 
adjustment for other comorbidities and clinical charac-
teristics. Furthermore, the principle definitions of MetS 
have not been compared in large cohorts of patients with 
stable CAD.
Accordingly, the aims of the present study were to: 
(1) determine the independent association of MetS as 
defined by the National Cholesterol Education Program 
(NCEP) vs. the International Diabetes Federation (IDF) 
criteria with 20-year all-cause mortality outcome; (2) 
evaluate the heterogeneity of the association between 
MetS and mortality in important subgroups of patients.
Methods
Study population
The present study population comprised patients who 
were screened for participation in the Bezafibrate Infarc-
tion Prevention (BIP) trial between February 1990 and 
October 1992 and enrolled in the BIP Registry. The 
design and rationale of the BIP Registry and study were 
published previously [22, 23]. Of the 15,524 screened 
patients, only 3090 (20%) proceeded to be randomized in 
the prospective interventional 6-year BIP study that com-
pared Bezafibrate to placebo. As the intervention period 
ended more than 15  years ago we decided to include 
these patients in our analysis cohort.
Briefly, BIP Registry included 15,524 patients aged 
40–74  years with stable CAD fulfilling the following 
inclusion criteria: (1) documented myocardial infarc-
tion (MI) in the previous 5 years, (2) symptomatic stable 
angina pectoris and either a positive myocardial ischemia 
by radio-nuclear-scintigraphy, or  ≥60% stenosis of 1 of 
the major coronary arteries, demonstrated by coronary 
angiography, or (3) documented percutaneous translu-
minal coronary angioplasty (PTCA) or coronary artery 
bypass grafting (CABG) operation in the preceding 
6  months. Exclusion criteria included: diabetes mellitus 
requiring the use of insulin, severe heart failure, unstable 
angina, hepatic or renal failure, and current use of lipid-
modifying drugs.
All medical examination and biochemical blood-tests, 
historical medical data, as well as data on drug therapy 
were prospectively recorded and all vital signs measured.
After exclusion of those patients with missing labora-
tory values the final data set for the current study com-
prised of 15,413 patients. Median follow up duration was 
20 ± 5 years.
The study was approved by the institute’s internal 
review board and was performed according to the princi-
ples expressed in the Declaration of Helsinki and the eth-
ics policy of the institute.
Metabolic syndrome definitions
Currently, there are two major definitions for MetS: 
the International Diabetes Federation (IDF) [24, 25] 
and National Cholesterol Education Program–Third 
Adult Treatment Panel (NCEP) [26]. Accordingly, study 
patients were categorized by the presence or lack of MetS 
by the two separate definitions.
Diagnosis criteria
Patients who presented with three or more of the follow-
ing five risk factors were defined as having MetS accord-
ing to the NCEP:
1. Central obesity defined as waist circumference 
greater than established ethnicity specific values. 
Since the data regarding waist circumference were 
not available, for purposes of this analysis we used 
the accepted body mass index (BMI) above 30 as a 
criterion for classifying patients as obese [25, 27].
2. Low high-density lipoprotein (HDL)  <50  mg/dL 
among women, and <40 mg/dL among men.
3. Elevated fasting plasma triglycerides (TG) ≥150 mg/
dL, or specific treatment for this lipid abnormality.
4. Elevated systolic blood pressure  ≥130  mm Hg, or 
diastolic value  ≥85  mm Hg, or treatment of previ-
ously diagnosed hypertension.
5. Elevated fasting plasma glucose (FPG) ≥100  mg/dL 
or previously diagnosed diabetes mellitus.
The definition of the MetS according to the IDF has 
some modifications as it requires central obesity as an 
obligatory criterion, and two or more of the other criteria 
as detailed above. Central obesity can be substituted by 
BMI >30 [25, 27, 28].
Patients were defined as diabetics based on their medi-
cal record diagnosis as prospectively coded at study 
entry. The same method was applied to the definitions 
of hypertension, smoking status and other elements of 
medical history. Patients with diabetes were considered 
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in this analysis as having impaired fasting glucose even if 
their point measurement of FPG was below 100 mg/dL.
Laboratory methods
Blood samples were drawn after at least 12 h of fasting. 
Cooled samples, collected in the 18 participating centers 
using standard equipment and procedures, were trans-
ferred to the study’s central laboratory. All analyses were 
performed on a Boehringer Hitachi 704 random access 
analyzer using Boehringer diagnostic kits. Detailed data 
on laboratory methods were given in a previous report 
[29].
Primary end point
The primary end point of this study was all-cause mortal-
ity. Mortality data was obtained by matching the patient’s 
identification numbers with their vital status available in 
the National Population Registry of Israel. Each match 
record was checked for correct identification by match-
ing the date of birth coded during survey enrollment 
with the date of birth available from the national regis-
try. Patients with missing values or inconsistent matching 
were excluded from the present analysis (n = 111).
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation (SD), and categorical data are summarized as 
percentages. The clinical characteristics of the patients 
at baseline by presence of the MetS were compared with 
the use of the unpaired t test for continuous variables or 
Mann–Whitney as appropriate, and the Chi square test 
for categorical variables.
The Kaplan–Meier method was used to calculate cumu-
lative survival curves for patients with and without MetS 
and the curves were compared using a Log rank test.
Multivariate Cox proportional hazard regression 
modeling was used to assess the independent effect of 
the MetS on the primary end point of all-cause mortal-
ity. The following covariates were introduced using the 
best subset method, following a univariate analysis of all 
relevant variables: age, gender, smoking status, creati-
nine concentration, diagnosis of diabetes mellitus (DM), 
hypertension, heart failure NYHA  >2, previous MI or 
past cerebrovascular accident (CVA). We additionally 
performed multivariate analysis as described above and 
included medication (anti-platelets, nitrates, calcium 
channel blockers, beta blockers and diuretics) as addi-
tional covariates.
Proportionality of hazard assumption was verified 
using Schoenfeld residuals and the log minus log (LML) 
method. We additionally performed a sensitivity analysis 
excluding patients randomized to the BIP randomized 
study (n = 3090).
In order to further explore the independent risk associ-
ated with the presence of MetS in pre-specified patient 
subgroups we performed interaction term analysis by 
the introduction of an MetS-by-risk-subgroup interac-
tion-term to the multivariate age adjusted Cox model 
(MetS by age interaction was not further adjusted). 
The following pre-specified subgroups were explored: 
age ≥65 years, gender, prior MI, renal dysfunction [serum 
creatinine >1.5 mg/dL], and New York Heart Association 
(NYHA) class >2. Interaction analysis is graphically pre-
sented in the form of a Forest plot.
Furthermore, in order to confirm our findings, an addi-
tional sensitivity analysis was performed, in which the 
waist circumference\BMI criteria were excluded, and the 
diagnosis of MetS was made if patients had two out of the 
four remaining criteria.
Statistical significance was declared for a two-sided 
p < 0.05. The statistical analysis was performed with IBM 
SPSS version 20.0 (Chicago, IL, USA) and SAS version 
9.2 (SAS institute Inc.) statistical software.
Results
Based on the criteria of the IDF 2122 (14%) patients had 
MetS, compared to 13,291 (86%) patients without the 
MetS, whereas based on the NCEP criteria 7446 (48%) 
patients had MetS, and 7967 (52%) were considered with-
out. Baseline characteristics of patients with and without 
MetS according to both definitions are summarized in 
Table 1.
As expected, patients with MetS had an adverse clini-
cal and biochemical profile, including higher incidence 
of diabetes, hypertension, hypercholesterolemia, and 
NYHA class >2. According to the IDF definition, patients 
with the MetS were slightly younger, with a male pre-
dominance, and had slightly lower serum creatinine con-
centration compared to patients without MetS (Table 1).
Prevalence of past CVA, and chronic obstructive lung 
disease (COPD) were similar. Low-density lipoprotein 
(LDL) levels and history of past MI were similar when 
MetS was defined by IDF criteria. When MetS was 
defined according to the NCEP criteria, past MI rates was 
similar between groups, however, LDL levels were higher 
in the MetS group vs. those without MetS (156 ± 36 vs. 
154 ± 33, p < 0.001).
Patients with the MetS were significantly more likely to 
receive beta-blockers, diuretics, calcium channel block-
ers and nitrates, and less likely to receive antiplatelet 
therapy (Table 1).
We further compared the individual components of 
MetS defined by the NCEP vs. the IDF criteria (Addi-
tional file  1: Table S1). Patients categorized accord-
ing to the NCEP definition were more likely to have 
other metabolic components (hypertension, IFG, 
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hypertriglyceridemia and low HDL) with the exception of 
BMI >30 that was present in only 28% of the NCEP group 
vs. 100% of the IDF group (all p value < 0.001).
Long‑term mortality by the presence of MetS
Kaplan–Meier survival analysis showed that at 20 years of 
follow-up all-cause mortality probability was significantly 
higher among patients with MetS vs. those without MetS 
(Fig. 1). When defined by the IDF criteria the respective 
cumulative mortality probability at 20  years were 1429 
(67%) and 8095 (61%) (p < 0.001 for the overall compari-
son during follow-up; Fig. 1a), and when defined by the 
NCEP criteria the respective rates were 4987 (67%) and 
4329 (54%) (p  <  0.001 for the overall comparison dur-
ing follow-up; Fig. 1b). Notably, separation in event rates 
between MetS and non-MetS patients appeared after 
approximately one year and was sustained thereafter.
Consistently, multivariate adjusted for: age, gen-
der, smoking status and major comorbidities (Creati-
nine >1.5 mg/dL, DM, HTN, past MI, previous CVA and 
NYHA  >2), MetS defined by the NCEP was associated 
with a significant 21% independent increased mortality 
risk (HR 1.21; 95% CI 1.13–1.29; Table 2a) whereas MetS 
defined by the IDF, was similarly independently associ-
ated with a 17% increased all-cause mortality risk (HR 
1.17; 95% CI 1.07–1.28; Table 2b). Consistent results were 
Table 1 Baseline characteristics of the study population by the two metabolic syndrome definitions
BMI body mass index; BP blood pressure; CHO total cholesterol; COPD chronic obstructive pulmonary disease; Creat creatinine; CVA cerebral vascular accident; DM 
diabetes mellitus; FPG fasting plasma glucose; HDL high-density lipoprotein; HTN hypertension; IDF International Diabetes Federation; LDL low density lipoprotein; MI 
myocardial infarction; NCEP National Cholesterol Educational Program; NYHA New York Heart Association; TG triglycerides
a Continuous variables are reported as mean ± standard deviation if normally distributed; otherwise, as median with 25th–75th range. Categorical variables are 
reported as numbers (%)
b Low HDL defined as HDL <40 mg/dL in males and HDL <50 mg/dL in females
c Systolic blood-pressure >130 mmHg or/and diastolic blood-pressure >85 mmHg
Metabolic IDF definition P value Metabolic NCEP definition P value
No (n = 13,291) Yes (n = 2122) No (n = 7967) Yes (n = 7446)
Age (years)a 60 ± 7 59 ± 7 <0.001 60 ± 7 60 ± 7 0.29
Male gender 10,910 (82%) 1540 (73%) <0.001 6600 (83%) 5850 (78%) <0.001
Active smoker 1485 (11%) 276 (13%) <0.001 832 (47%) 929 (53%) <0.001
HTN 4197 (32%) 948 (45%) <0.001 2197 (27%) 2948 (40%) <0.001
DM 2355 (18%) 604 (29%) <0.001 784 (10%) 2175 (30%) <0.001
COPD 382 (3%) 70 (3%) 0.27 238 (3%) 214 (3%) 0.85
Past MI 9611 (72%) 1519 (72%) 0.91 5754 (72%) 5376 (72%) 0.92
Past CVA 236 (1.8%) 33 (1.6%) 0.47 131 (1.6%) 138 (1.9%) 0.26
NYHA class >2 753 (5%) 185 (9%) <0.001 409 (5%) 491 (6.8%) <0.001
Laboratory values (mg/dL)
 Creata 1.15 ± 0.2 1.11 ± 0.2 <0.001 1.15 ± 0.2 1.14 ± 0.2 0.02
 CHOa 224 ± 39 228 ± 42 <0.001 212 ± 37 228 ± 41 <0.001
 LDLa 155 ± 34 155 ± 37 0.73 154 ± 33 156 ± 36 <0.001
Medication
 Bezafibrate 1369 (10%) 193 (9%) 0.10 784 (10%) 778 (10%) 0.22
 Placebo 1347 (10%) 210 (10%) 0.68 760 (9.5%) 797 (11%) 0.02
 Beta-blockers 4527 (34%) 873 (41%) <0.001 2484 (31%) 2916 (39%) <0.001
 Nitrates 6568 (49%) 1150 (54%) <0.001 3856 (48%) 3861 (51%) <0.01
 CCB 6555 (49%) 1160 (54%) <0.001 3904 (49%) 3810 (51%) <0.01
 Diuretics 1926 (14%) 449 (21%) <0.001 1018 (13%) 1356 (18%) <0.001
 Anti-platelets agents 7934 (59%) 1136 (53%) <0.001 4867 (61%) 4203 (56%) <0.001
Components of the metabolic syndrome
 FPG >100 mg/dL 5805 (44%) 1412 (67%) <0.001 1873 (23%) 5347 (72%) <0.001
 Low HDLb 9155 (73%) 1858 (90%) <0.001 4065 (56%) 6948 (94%) <0.001
 TG >150 mg/dL 5226 (40%) 1297 (61%) <0.001 1198 (15%) 5325 (72%) <0.001
 BMI >30 kg/m2 340 (2.6%) 2122 (100%) <0.001 340 (4%) 2122 (28%) <0.001
 Elevated BPc 8978 (68%) 1761 (83%) <0.001 4329 (54%) 6410 (86%) <0.001
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obtained when patients randomized to the interventional 
BIP trial (n = 3090) were excluded or when medications 
were adjusted for. The mortality risk associated with MetS 
was similar when BMI was excluded, and patients were 
defined based only on two out of remaining four criteria.
Increased serum creatinine, the presence of diabetes 
mellitus, current smoking and a history of myocardial 
infarction were additional independent predictors of all-
cause mortality (Table 2a, b).
Subgroup analysis
We further explored the independent association 
between the presence of MetS and long-term mortality 
in predefined subgroups of patients (Fig. 2). This analysis 
showed that the mortality risk was increased by 15–25% 
across all major groups when both definitions of MetS 
were used, with the exception of patients with creati-
nine concentration  >1.5  mg/dL (p value of interaction 
p =  0.04) and those 65  years old or older, when NCEP 
definition was used (p value for interaction  =  0.003; 
Fig. 2a, b).
Discussion
The primary findings of our study are: (1) MetS is asso-
ciated with approximately 20% greater all-cause mortal-
ity risk at 20-year of follow-up; the risk is independent 
of other important predictors of adverse outcomes; (2) 
The two leading definitions of MetS, respectively IDF and 
NCEP criteria, have similar long-term prognostic impli-
cations despite the inclusion of a much greater number 
of patients according to the NCEP definition; (3) the 
mortality risk associated with MetS is consistent in most 
patient subgroups, with the possible exception of those 
with renal dysfunction and less pronounced in patients 
aged 65 years or older.
Fig. 1 Kaplan-Meier 20-year survival estimates for the entire cohort. 
a Survival estimates according to the presence or absence of the 
metabolic syndrome according to the IDF definition. b Survival 
estimates according to the presence or absence of metabolic syn-
drome according to the NCEP definition. Cre creatinine; DM diabetes 
mellitus; IDF International Diabetes Federation; LDL low density 
lipoprotein; MetS metabolic syndrome; MI myocardial infarction; NCEP 
National Cholesterol Educational Program
Table 2 Independent all-cause mortality risk predictors 
in patients with stable CAD using the (a) NCEP and (b) IDF 
MetS definition
Both models further adjusted for: hypertension, smoking status, and severe 
heart failure (NYHA >2)
CI 95% confidence interval; CVA cerebral-vascular accident; HR hazard ratio; 
MI myocardial infarction; NCEP National Cholesterol Education Program; IDF 
International Diabetes Federation; NYHA New York Heart Association
Adjusted HR 95% CI for upper P value
(a) Hazard ration among the NCEP metabolic group
Metabolic NCEP 1.21 1.14–1.29 <0.001
 Age >65 years 1.08 1.07–1.08 <0.001
 Male gender 1.19 1.09–1.31 <0.001
 Creatinine >1.5 mg/dL 1.59 1.38–1.84 <0.001
 Diabetes mellitus 1.61 1.49–1.74 <0.001
 Hypertension 1.08 1.01–1.15 0.01
 Past MI 1.41 1.31–1.52 <0.001
 Previous CVA 1.07 0.83–1.39 0.59
 NYHA >2 1.25 1.10–1.43 <0.001
 Active smoker 1.57 1.43–1.71 <0.001
(b) Hazard ration among the IDF metabolic group
Metabolic IDF 1.17 1.07–1.28 <0.001
 Age >65 years 1.08 1.08–1.09 <0.001
 Male gender 1.17 1.06–1.29 <0.001
 Creatinine >1.5 mg/dL 1.60 1.38–1.84 <0.001
 Diabetes mellitus 1.68 1.56–1.81 <0.001
 Hypertension 1.10 1.04–1.18 0.003
 Past MI 1.41 1.31–1.52 <0.001
 Previous CVA 1.10 0.85–1.42 0.48
 NYHA >2 1.23 1.07–1.41 0.003
 Active smoker 1.57 1.43–1.72 <0.001
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A number of prior large-scale studies demonstrated the 
long-term prognostic significance of every single meta-
bolic component of the MetS [15, 30–33], whereas contro-
versy remains regarding additional value of the MetS in the 
risk estimation on top of its individual components [28, 
34–39].
Although earlier studies tend to show a significant asso-
ciation between MetS and all-cause mortality especially 
among middle-aged individuals similar to our cohort, 
[10, 40–42] they were shorter in duration [17, 20, 43, 44], 
had smaller samples [45–47], had cardiovascular mortal-
ity as their primary outcome and comprised mostly of 
patients after an intervention [17, 20, 43–47]. In studies 
by Marso et al. and Miller et al. patients with acute coro-
nary syndrome were enrolled, rather than patients with a 
stable coronary disease [32, 33].
On the other hand, more recent studies, who enrolled 
patients with ACS were unable to demonstrate such an 
association in coronary patients after ACS or revasculari-
zation. [48, 49].
The largest meta-analysis that included near one mil-
lion patients (total n = 951,083) concluded that the MetS 
is associated with a twofold increase in cardiovascular 
outcomes and a 1.5-fold increase in all-cause mortality 
Fig. 2 Mortality risk associated with metabolic syndrome presence according to the IDF (a) and NCEP definitions (b) in pre-specified subgroups. 
Both models further adjusted for: hypertension, smoking status, and severe heart failure (NYHA >2). Cre creatinine; DM diabetes mellitus; IDF Inter-
national Diabetes Federation; LDL low density lipoprotein; MetS metabolic syndrome; MI myocardial infarction; NCEP National Cholesterol Educa-
tional Program
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rates [42]. Nevertheless, most subjects included in this 
analysis had no overt cardiovascular disease.
One recent large study by van Herpt et  al. has shown 
that MetS increased the all-cause mortality in univariate 
analysis, yet was unable to find any significant associa-
tions of MetS with all-cause mortality after adjustment 
for age, gender and comorbidities. [39].
Additionally, previous studies were limited by their 
small size and relatively modest follow-up period, which 
was mostly less than 3  years in the majority of studies 
concerning the MetS and mortality. [16–21] Furthermore 
these studies have explored the cardiovascular mortality 
rather than all-cause mortality as their primary outcome. 
[16–21].
Hence the enrollment for this study took place between 
the years 1990 and 1992, the majority of the patients 
didn’t undergo revascularization at the time of their 
enrollment. While most studies that evaluated patients 
after a recent acute coronary syndrome [14, 15, 30] or 
after coronary revascularization [16–21] failed to show 
a significant effects of MetS on mortality among patients 
with stable coronary artery disease and without revas-
cularization, our study did find a significant association 
with all-cause mortality.
To the best of our knowledge, our study is the largest 
and presents the longest follow-up period of patients 
with stable CAD demonstrating an independent associa-
tion of MetS with all-cause mortality.
Despite the significant numeric difference, and the sig-
nificant difference of their metabolic components, both 
MetS groups (IDF and NCEP definitions), had almost a 
similar effect on the 20-year all-cause mortality outcome, 
regardless of the definition employed.
Notably, the number of patients with MetS according 
to NCEP criteria was significantly larger than the num-
ber obtained when the IDF criteria were utilized (7446 
vs. 2122). This difference is due to the obligatory inclu-
sion of the central obesity as a required according to 
the IDF criteria, in addition to the two or more of the 
remaining 4 criteria detailed above. In contrast, the 
NCEP does not present such an obligatory requirement 
and is based on the presence of any three criteria. This 
leads to the fact that all IDF patients are also included in 
the NCEP group.
Despite the fact that the presence of the MetS possesses 
a definite predictive value, the view of this metabolic clus-
ter as a prognostic tool only will be too simplistic. MetS 
is a widely accepted concept regarding a biological condi-
tion based on the complex and interrelated pathophysio-
logical mechanisms starting from excess central adiposity 
and insulin resistance. MetS identifies additional impor-
tant residual vascular risk mainly associated with insulin 
resistance, atherogenic dyslipidemia, non-alcoholic fatty 
liver and type 2 diabetes development. Therefore, the 
MetS could be a useful additional contributor in estima-
tion of global cardiovascular risk beyond its components 
and other standard risk factors like age, high LDL-C, etc. 
[50–55].
Moreover, the concept that the metabolic syndrome is 
a consequence of obesity and insulin resistance, provides 
a useful “life-style changes” approach for prevention and 
treatment: caloric restriction, weight-loss and increased 
physical activity within cardiac rehabilitation programs 
for patients with CAD.
Limitations
Our study has a number of limitations. First, it is a ret-
rospective study that enrolled patients during a period 
where different treatments were used for controlling 
blood glucose, hyperlipidemia and hypertension, thus our 
results warrant validation in more contemporary popula-
tions. Second, not all confounders can be accounted for 
nor were all possible variables measured at enrolment. 
Third, we have no data regarding clinical events and 
clinical management after the screening period. Finally, 
our data lacks waist circumference assessment which is 
important element of the definition of central obesity as 
a component of the MetS. However, we replaced this cri-
teria with the BMI >30 according to the consensus of the 
IDF and NCEP. Furthermore, when we excluded the BMI 
criteria, and set the diagnosis of MetS as the presence of 
two out the four remaining criteria, similar results were 
obtained.
Conclusions
Metabolic syndrome is independently associated with 
increased 20-year mortality in patients with stable coro-
nary artery disease. The excess of the very long-term 
mortality risk was consistent regardless of the MetS 
definition employed and similar across most population 
subgroups, yet less pronounced in patients of 65 year or 
older and absent in patients with renal failure.
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